Symbols / IFRX
IFRX Chart
About
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 59.75M |
| Enterprise Value | 16.34M | Income | -40.10M | Sales | 62.84K |
| Book/sh | 0.79 | Cash/sh | 0.66 | Dividend Yield | — |
| Payout | 0.00% | Employees | 74 | IPO | — |
| P/E | — | Forward P/E | -1.09 | PEG | — |
| P/S | 950.78 | P/B | 1.12 | P/C | — |
| EV/EBITDA | -0.35 | EV/Sales | 260.11 | Quick Ratio | 2.43 |
| Current Ratio | 3.33 | Debt/Eq | 2.14 | LT Debt/Eq | — |
| EPS (ttm) | -0.72 | EPS next Y | -0.81 | EPS Growth | — |
| Revenue Growth | -80.80% | Earnings | 2026-03-19 | ROA | -40.69% |
| ROE | -72.49% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -420.15% | Profit Margin | 0.00% | Shs Outstand | 67.75M |
| Shs Float | 55.49M | Short Float | 5.02% | Short Ratio | 4.78 |
| Short Interest | — | 52W High | 1.94 | 52W Low | 0.71 |
| Beta | 1.50 | Avg Volume | 604.63K | Volume | 120.55K |
| Target Price | $10.43 | Recom | None | Prev Close | $0.89 |
| Price | $0.88 | Change | -0.40% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.45
Mean price target
2. Current target
$0.88
Latest analyst target
3. DCF / Fair value
$2.39
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.88
Low
$1.98
High
$24.32
Mean
$10.45
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-30 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-12-03 | down | Leerink Partners | Outperform → Market Perform | $2 |
| 2025-11-10 | main | Guggenheim | Buy → Buy | $22 |
| 2025-05-29 | main | Oppenheimer | Outperform → Outperform | $3 |
| 2025-05-08 | init | Oppenheimer | — → Outperform | $6 |
| 2025-04-29 | init | Cantor Fitzgerald | — → Overweight | $10 |
| 2025-03-26 | main | Guggenheim | Buy → Buy | $10 |
| 2025-03-21 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-01-16 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-12-20 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-09-25 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-06-24 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-06-06 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-05-09 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-03-22 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-01-25 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2023-11-02 | main | Raymond James | Strong Buy → Strong Buy | $19 |
- Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely - Yahoo Finance Mon, 02 Feb 2026 08
- Guggenheim Maintains InflaRx N.V. (IFRX) Buy Recommendation - Nasdaq Mon, 10 Nov 2025 08
- With InflaRx Stock Sliding, Have You Assessed The Risk? - Trefis Sun, 21 Dec 2025 08
- InflaRx (NASDAQ: IFRX) to share Phase 2a INF904 data; pre-market release and webcast - Stock Titan Fri, 07 Nov 2025 08
- InflaRx: Gohibic Remains Niche, INF904 Underwhelms, Cash Burn Accelerates (Rating Downgrade) - Seeking Alpha Wed, 19 Nov 2025 08
- New Analyst Forecast: $IFRX Given $6 Price Target | IFRX Stock News - Quiver Quantitative ue, 30 Dec 2025 08
- IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases - Stocktwits Mon, 10 Nov 2025 08
- InflaRx (IFRX): Assessing Valuation After Positive Phase 2a Results for INF904 in HS and CSU - simplywall.st Wed, 12 Nov 2025 08
- Inflarx stock price target raised to $9 from $2 at Raymond James on HS drug data - Investing.com ue, 11 Nov 2025 08
- InflaRx Announces Positive Phase 2a Results for INF904 in HS and CSU - TipRanks Mon, 10 Nov 2025 08
- After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers - Nasdaq Sun, 09 Nov 2025 08
- InflaRx (Nasdaq: IFRX) receives WHO INN 'izicopan' for oral C5aR inhibitor INF904 - Stock Titan hu, 11 Dec 2025 08
- InflaRx (IFRX) Is Up 17.7% After INF904 Shows Promising Results in Phase 2a Study—What's Changed - Yahoo Finance Wed, 12 Nov 2025 08
- InflaRx stock plunges on plans to drop lead asset (IFRX:NASDAQ) - Seeking Alpha Wed, 28 May 2025 07
- InflaRx N.V. to Report Topline Data and Q3 2025 Financial Results on November 10, 2025 - Quiver Quantitative Fri, 07 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 770.75K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -49.22M | -40.22M | -31.29M | -46.90M |
| TotalUnusualItems | 3.67M | -1.84M | 2.44M | 1.96M |
| TotalUnusualItemsExcludingGoodwill | 3.67M | -1.84M | 2.44M | 1.96M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -46.06M | -42.67M | -29.48M | -45.63M |
| ReconciledDepreciation | 485.11K | 567.78K | 596.60K | 669.43K |
| ReconciledCostOfRevenue | 3.29M | 472.39K | 0.00 | 0.00 |
| EBITDA | -45.55M | -42.06M | -28.84M | -44.94M |
| EBIT | -46.04M | -42.63M | -29.44M | -45.61M |
| NetInterestIncome | 3.28M | 4.08M | 310.96K | 40.62K |
| InterestExpense | 20.66K | 35.63K | 45.25K | 24.77K |
| InterestIncome | 3.20M | 3.80M | 608.68K | 109.39K |
| NormalizedIncome | -48.96M | -40.83M | -31.93M | -47.59M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -46.06M | -42.67M | -29.48M | -45.63M |
| TotalExpenses | 53.17M | 44.97M | 32.24M | 47.63M |
| TotalOperatingIncomeAsReported | -53.01M | -44.91M | -32.24M | -47.63M |
| DilutedAverageShares | 58.92M | 54.94M | 44.21M | 41.63M |
| BasicAverageShares | 58.92M | 54.94M | 44.21M | 41.63M |
| DilutedEPS | -0.78 | -0.78 | -0.67 | -1.10 |
| BasicEPS | -0.78 | -0.78 | -0.67 | -1.10 |
| DilutedNIAvailtoComStockholders | -46.06M | -42.67M | -29.48M | -45.63M |
| NetIncomeCommonStockholders | -46.06M | -42.67M | -29.48M | -45.63M |
| NetIncome | -46.06M | -42.67M | -29.48M | -45.63M |
| NetIncomeIncludingNoncontrollingInterests | -46.06M | -42.67M | -29.48M | -45.63M |
| NetIncomeContinuousOperations | -46.06M | -42.67M | -29.48M | -45.63M |
| TaxProvision | 5.22K | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -46.06M | -42.67M | -29.48M | -45.63M |
| OtherIncomeExpense | 3.67M | -1.84M | 2.44M | 1.96M |
| GainOnSaleOfSecurity | 3.67M | -1.84M | 2.44M | 1.96M |
| NetNonOperatingInterestIncomeExpense | 3.28M | 4.08M | 310.96K | 40.62K |
| TotalOtherFinanceCost | -103.28K | -313.24K | 252.47K | 44.00K |
| InterestExpenseNonOperating | 20.66K | 35.63K | 45.25K | 24.77K |
| InterestIncomeNonOperating | 3.20M | 3.80M | 608.68K | 109.39K |
| OperatingIncome | -53.01M | -44.91M | -32.24M | -47.63M |
| OperatingExpense | 49.86M | 44.44M | 32.24M | 47.63M |
| OtherOperatingExpenses | -5.29M | -13.22M | -20.16M | -47.84K |
| DepreciationAmortizationDepletionIncomeStatement | 455.50K | 507.90K | 526.33K | 551.57K |
| DepreciationAndAmortizationInIncomeStatement | 455.50K | 507.90K | 526.33K | 551.57K |
| ResearchAndDevelopment | 35.36M | 41.02M | 37.53M | 35.70M |
| SellingGeneralAndAdministration | 19.33M | 16.12M | 14.34M | 11.43M |
| SellingAndMarketingExpense | 4.04M | 1.91M | 0.00 | 0.00 |
| GeneralAndAdministrativeExpense | 15.29M | 14.22M | 14.34M | 11.43M |
| OtherGandA | 5.25M | 5.54M | 4.64M | 3.05M |
| InsuranceAndClaims | 1.57M | 1.93M | 2.33M | 1.62M |
| SalariesAndWages | 8.47M | 6.74M | 7.37M | 6.77M |
| GrossProfit | -3.15M | -469.17K | 0.00 | 0.00 |
| CostOfRevenue | 3.32M | 532.26K | 0.00 | 0.00 |
| TotalRevenue | 165.79K | 63.09K | 0.00 | 0.00 |
| OperatingRevenue | 165.79K | 63.09K | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 59.35M | 58.88M | 44.70M | 44.20M |
| ShareIssued | 59.35M | 58.88M | 44.70M | 44.20M |
| TotalDebt | 805.09K | 1.12M | 1.36M | 1.43M |
| TangibleBookValue | 61.37M | 102.51M | 88.21M | 105.05M |
| InvestedCapital | 61.42M | 102.58M | 88.35M | 105.28M |
| WorkingCapital | 57.49M | 92.62M | 84.39M | 76.92M |
| NetTangibleAssets | 61.37M | 102.51M | 88.21M | 105.05M |
| CapitalLeaseObligations | 805.09K | 1.12M | 1.36M | 1.43M |
| CommonStockEquity | 61.42M | 102.58M | 88.35M | 105.28M |
| TotalCapitalization | 61.42M | 102.58M | 88.35M | 105.28M |
| TotalEquityGrossMinorityInterest | 61.42M | 102.58M | 88.35M | 105.28M |
| StockholdersEquity | 61.42M | 102.58M | 88.35M | 105.28M |
| OtherEquityInterest | 7.44M | 7.38M | 7.26M | 3.05M |
| GainsLossesNotAffectingRetainedEarnings | 44.12M | 40.05M | 36.64M | 30.59M |
| OtherEquityAdjustments | 44.12M | 40.05M | 36.64M | 30.59M |
| RetainedEarnings | -332.19M | -286.13M | -243.46M | -213.98M |
| AdditionalPaidInCapital | 334.93M | 334.21M | 282.55M | 280.31M |
| CapitalStock | 7.12M | 7.07M | 5.36M | 5.30M |
| CommonStock | 7.12M | 7.07M | 5.36M | 5.30M |
| TotalLiabilitiesNetMinorityInterest | 14.60M | 17.63M | 14.05M | 19.86M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 435.94K | 782.59K | 1.02M | 1.10M |
| OtherNonCurrentLiabilities | 36.88K | 36.88K | 36.88K | 35.02K |
| LongTermDebtAndCapitalLeaseObligation | 399.07K | 745.72K | 987.31K | 1.07M |
| LongTermCapitalLeaseObligation | 399.07K | 745.72K | 987.31K | 1.07M |
| CurrentLiabilities | 14.17M | 16.84M | 13.03M | 18.76M |
| OtherCurrentLiabilities | 301.55K | 2.89M | 147.61K | 138.21K |
| CurrentDeferredLiabilities | 0.00 | 6.21M | 8.30M | |
| CurrentDeferredRevenue | 0.00 | 6.21M | 8.30M | |
| CurrentDebtAndCapitalLeaseObligation | 406.02K | 374.33K | 369.38K | 366.17K |
| CurrentCapitalLeaseObligation | 406.02K | 374.33K | 369.38K | 366.17K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.06M | 1.61M | 1.31M | 1.38M |
| PayablesAndAccruedExpenses | 11.39M | 11.97M | 4.99M | 8.57M |
| CurrentAccruedExpenses | 3.42M | 6.89M | ||
| Payables | 11.39M | 11.97M | 4.99M | 1.69M |
| AccountsPayable | 11.39M | 11.97M | 4.99M | 1.69M |
| TotalAssets | 76.02M | 120.21M | 102.40M | 125.14M |
| TotalNonCurrentAssets | 4.36M | 10.74M | 4.99M | 29.46M |
| OtherNonCurrentAssets | 1.00 | 1.00 | 1.00 | |
| NonCurrentPrepaidAssets | 204.23K | 257.27K | 308.07K | 336.57K |
| InvestmentsAndAdvances | 3.09M | 9.05M | 2.90M | 27.21M |
| InvestmentinFinancialAssets | 3.09M | 9.05M | 2.90M | 27.21M |
| HeldToMaturitySecurities | 9.05M | 2.90M | 27.21M | |
| AvailableForSaleSecurities | 3.09M | 9.05M | ||
| GoodwillAndOtherIntangibleAssets | 50.78K | 68.82K | 138.91K | 235.22K |
| OtherIntangibleAssets | 50.78K | 68.82K | 138.91K | 235.22K |
| NetPPE | 1.01M | 1.36M | 1.64M | 1.68M |
| AccumulatedDepreciation | -3.45M | -2.97M | -2.52M | -1.99M |
| GrossPPE | 4.46M | 4.33M | 4.16M | 3.68M |
| ConstructionInProgress | 0.00 | 0.00 | 0.00 | |
| OtherProperties | 1.54M | 1.49M | 1.45M | 1.27M |
| MachineryFurnitureEquipment | 242.74K | 174.13K | 125.13K | 125.13K |
| BuildingsAndImprovements | 2.68M | 2.66M | 2.58M | 2.28M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 71.66M | 109.47M | 97.41M | 95.68M |
| OtherCurrentAssets | 5.20M | 93.48K | 2.55M | |
| PrepaidAssets | 4.98M | 3.94M | 11.62M | 10.98M |
| Inventory | 6.90M | 11.37M | 0.00 | |
| OtherInventories | 1.00 | |||
| FinishedGoods | 56.63K | 330.09K | 0.00 | |
| WorkInProcess | 6.76M | 10.61M | 0.00 | |
| RawMaterials | 82.09K | 423.56K | 0.00 | |
| Receivables | 1.74M | 3.79M | 1.43M | 1.28M |
| TaxesReceivable | 1.74M | 3.79M | 1.43M | 1.28M |
| CashCashEquivalentsAndShortTermInvestments | 52.84M | 90.27M | 81.81M | 83.41M |
| OtherShortTermInvestments | 34.46M | 77.50M | 65.54M | 57.16M |
| CashAndCashEquivalents | 18.38M | 12.77M | 16.27M | 26.25M |
| CashEquivalents | 14.11M | 5.14M | 3.42K | 12.58M |
| CashFinancial | 4.27M | 7.63M | 16.26M | 13.67M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -48.60M | -37.89M | -33.91M | -39.97M |
| RepaymentOfDebt | -388.11K | -373.98K | -364.43K | -360.64K |
| IssuanceOfCapitalStock | 1.10M | 56.48M | 2.35M | 65.14M |
| CapitalExpenditure | -46.87K | -81.10K | -162.39K | -37.78K |
| EndCashPosition | 18.38M | 12.77M | 16.27M | 26.25M |
| BeginningCashPosition | 12.77M | 16.27M | 26.25M | 25.97M |
| EffectOfExchangeRateChanges | 1.41M | -974.10K | 2.46M | 4.59M |
| ChangesInCash | 4.19M | -2.52M | -12.45M | -4.31M |
| FinancingCashFlow | 386.45K | 52.99M | 1.94M | 61.58M |
| CashFlowFromContinuingFinancingActivities | 386.45K | 52.99M | 1.94M | 61.58M |
| NetOtherFinancingCharges | -323.73K | -3.36M | -47.73K | -4.22M |
| ProceedsFromStockOptionExercised | 0.00 | 236.94K | 0.00 | 1.01M |
| NetCommonStockIssuance | 1.10M | 56.48M | 2.35M | 65.14M |
| CommonStockIssuance | 1.10M | 56.48M | 2.35M | 65.14M |
| NetIssuancePaymentsOfDebt | -388.11K | -373.98K | -364.43K | -360.64K |
| NetLongTermDebtIssuance | -388.11K | -373.98K | -364.43K | -360.64K |
| LongTermDebtPayments | -388.11K | -373.98K | -364.43K | -360.64K |
| InvestingCashFlow | 52.36M | -17.70M | 19.36M | -25.95M |
| CashFlowFromContinuingInvestingActivities | 52.36M | -17.70M | 19.36M | -25.95M |
| NetOtherInvestingChanges | 1.00 | |||
| NetInvestmentPurchaseAndSale | 52.41M | -17.62M | 19.52M | -25.91M |
| SaleOfInvestment | 87.75M | 86.44M | 84.00M | 71.60M |
| PurchaseOfInvestment | -35.34M | -104.05M | -64.47M | -97.52M |
| NetIntangiblesPurchaseAndSale | -46.87K | -81.10K | -162.39K | -37.78K |
| PurchaseOfIntangibles | -46.87K | -81.10K | -162.39K | -37.78K |
| OperatingCashFlow | -48.56M | -37.81M | -33.74M | -39.94M |
| CashFlowFromContinuingOperatingActivities | -48.56M | -37.81M | -33.74M | -39.94M |
| InterestReceivedCFO | 2.24M | 1.73M | 1.29M | 1.07M |
| InterestPaidCFO | -21.06K | -36.02K | -44.95K | -23.63K |
| ChangeInWorkingCapital | -2.28M | 1.00M | -9.77M | 1.54M |
| ChangeInOtherWorkingCapital | 454.91K | 297.52K | -64.02K | -3.29K |
| ChangeInOtherCurrentLiabilities | -2.58M | -3.47M | -2.08M | 8.32M |
| ChangeInOtherCurrentAssets | -4.04M | 8.56M | -4.04M | -7.09M |
| ChangeInPayablesAndAccruedExpense | -580.13K | 6.99M | -3.59M | 316.11K |
| ChangeInPayable | -580.13K | 6.99M | -3.59M | 316.11K |
| ChangeInInventory | 4.47M | -11.37M | 0.00 | 0.00 |
| OtherNonCashItems | -6.95M | -2.24M | -2.75M | -2.00M |
| StockBasedCompensation | 4.07M | 3.41M | 6.04M | 4.33M |
| DepreciationAmortizationDepletion | 485.11K | 567.78K | 596.60K | 669.43K |
| DepreciationAndAmortization | 485.11K | 567.78K | 596.60K | 669.43K |
| AmortizationCashFlow | 42.19K | 96.06K | 98.27K | |
| AmortizationOfIntangibles | 42.19K | 96.06K | 98.27K | |
| Depreciation | 442.93K | 471.72K | 498.33K | |
| OperatingGainsLosses | -37.10K | 413.02K | 385.36K | 111.61K |
| NetForeignCurrencyExchangeGainLoss | -37.10K | 413.02K | 385.36K | 111.61K |
| NetIncomeFromContinuingOperations | -46.06M | -42.67M | -29.48M | -45.63M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for IFRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|